Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · January 21, 2024

Outcomes of Treatment With Pegbelfermin in Patients With NASH and Stage 3 Fibrosis

Clinical Gastroenterology and Hepatology


Additional Info

Clinical Gastroenterology and Hepatology
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Clin. Gastroenterol. Hepatol. 2024 Jan 01;22(1)102-112.e9, R Loomba, AJ Sanyal, A Nakajima, BA Neuschwander-Tetri, ZD Goodman, SA Harrison, EJ Lawitz, N Gunn, K Imajo, N Ravendhran, T Akahane, B Boone, M Yamaguchi, A Chatterjee, GS Tirucherai, DE Shevell, S Du, ED Charles, MF Abdelmalek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading